PerkinElmer

PerkinElmer, Inc. engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. It operates through the following segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment consists of technologies that help life sciences researchers better understand diseases and develop treatments. The Diagnostics segment offers instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians, and medical research professionals to help improve the health of families. The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937, and is headquartered in Waltham, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. With a global network and localized agility, the company serves a diverse range of organizations from pharmaceutical and biotech to clinical labs, academia, and governments. It is headquartered in Waltham, MA.

PerkinElmer's (PKI) partnership with ASH likely to boost newborn screening in underserved populations for better health outcomes in Africa.

PerkinElmer's Tie-Up to Boost Health Outcomes in Africa

Abbott Labs

Bio-Rad Laboratories

Independent analysis shows some of the post-exposure tests work fairly well.

FDA Evaluates 5 More COVID-19 Antibody Tests

PerkinElmer (PKI) reported earnings 30 days ago. What's next for the stock?

Why Is PerkinElmer (PKI) Up 11.4% Since Last Earnings Report?

PerkinElmer (PKI) continues to gain traction from strong international presence and robust product portfolio.

Why You Should Retain PerkinElmer (PKI) in Your Portfolio

PerkinElmer Inc. PKI, +0.04% said Monday that it has not received any information, and is not aware of any wrongdoing, as implied by a Reuters report.

PerkinElmer denies Reuters report that it is being investigated in a Medicare fraud case

Medical diagnostic firm PerkinElmer Inc  faces a federal investigation into its role in an alleged Medicare fraud involving tens of thousands of unnecessary genetic cancer tests, according to three sources with knowledge of the probe and documents reviewed by Reuters.

Exclusive: U.S. probes PerkinElmer's role in massive Medicare fraud - sources

PerkinElmer: The Market Completely Missed The Transformation

PerkinElmer, Inc. (PKI) CEO Prahlad Singh on Q1 2020 Results - Earnings Call Transcript

PerkinElmer (PKI) delivered earnings and revenue surprises of 42.55% and 1.75%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

PerkinElmer (PKI) Q1 Earnings and Revenues Beat Estimates

Harvard Bioscience

Mettler-Toledo

Waters

Drab Near-Term Prospects for Scientific Instruments Industry

New Linde PLC

Marsh & McLennan

The S&P 500 index, which is the main benchmark for the U.S. market, grew its total sales by 4.1% on average every year over the five years from Dec.

3 Stocks That Have  Grown Revenue Fast

PerkinElmer's (PKI) first-quarter results likely to reflect top-line growth and robust performance at Diagnostics segment. However, forex is likely to have remained a woe.

PerkinElmer (PKI) to Report Q1 Earnings: What's in Store?

Thermo Fisher Scientific

These key biotech and molecular diagnostic players banking on the receipt of FDA's EUA for COVID-19 tests are currently outperforming the broader industries they belong to.

FDA EUA for Coronavirus Tests Boosts MedTech: 3 Stocks in Focus (Revised)

FDA EUA for Coronavirus Tests Boosts MedTech: 3 Stocks in Focus

PerkinElmer (PKI) introduces test for the detection of coronavirus after it receives EUA for the same.

PerkinElmer (PKI) Receives EUA for Coronavirus Detection Test

PerkinElmer Inc. PKI, +9.52% said late Tuesday it received an emergency use authorization from the Food and Drug Administration so labs can start using its test for SARS-CoV-2, the virus that causes COVID-19.

PerkinElmer gets emergency OK from FDA for coronavirus test

PerkinElmer (PKI) Down 12.1% Since Last Earnings Report: Can It Rebound?

PerkinElmer's (PKI) Q4 earnings benefits from higher revenues and growth in DAS and Diagnostics segments. However, forex remains a woe.

PerkinElmer (PKI) Q4 Earnings and Revenues Beat Estimates

The global healthcare company beat analysts' estimates in Q4 but disappointed with its 2020 Q1 outlook.

What Investors Liked and Didn't Like About PerkinElmer's Q4 Earnings Results

PerkinElmer, Inc. (PKI) CEO Prahlad Singh on Q4 2019 Results - Earnings Call Transcript

F5 Networks

Whirlpool

Juniper Networks

Take a look at the companies making headlines after the bell.

Stocks making the biggest move after the bell: Whirlpool, F5 Networks, PerkinElmer and more

PerkinElmer (PKI) delivered earnings and revenue surprises of 2.27% and 0.44%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

PerkinElmer (PKI) Tops Q4 Earnings and Revenue Estimates

Top-line growth and robust performance at Diagnostics segment are likely to have aided PerkinElmer's (PKI) Q4 earnings. However, forex is likely to have remained a woe.

PerkinElmer (PKI) to Report Q4 Earnings: What's in the Cards?

Scientific Instruments Industry Outlook: Prospects Look Good

PerkinElmer (PKI) is gaining steadily from the core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.

News for PerkinElmer Stock (PKI)